Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Hepatology ; (12): 821-825, 2015.
Artigo em Chinês | WPRIM | ID: wpr-303224

RESUMO

<p><b>OBJECTIVE</b>To observe the clinical efficacy of combination therapy with peg-IFNalpha and adefovir (CPIA) in women who were hepatfis B virus (HBV) carriers and had just given birth and received telbivudine (LdT) during pregnancy for prevention of mother-to-child transmission.</p><p><b>METHODS</b>One-hundred-and-fifty third trimester-pregnant women who were HBV carriers with highly-viremic were treated with LdT until time of birth. After delivery, those women with alanine aminotransferase (ALT) level exceeding two times the upper limit of normal and HBV DNA level that had decreased more than 31 gIU/mL or hepatitis B e antigen (HBeAg) titer that had decreased more than 50% were switched to CPIA for 96 weeks.</p><p><b>RESULTS</b>Following delivery, 45 of the women were switched to the CPIA treatment, of which 91.1% (41/45) achieved virological response, 55.6% (25/45) achieved HBeAg clearance or seroconversion, and 26.7% (12/45) achieved hepatitis B surface antigen (HBsAg) clearance or seroconversion.The immediate post-delivery (and pre-CPIA) levels of HBeAg and HBV DNA were negatively associated with HBeAg clearance. Ninety-eight of the total study participants stopped the LdT treatment and there were no cases of significant deterioration of liver function.</p><p><b>CONCLUSION</b>Pregnant women who are HBV carriers and receive LdT for protection against mother-to-child transmission, and who show significant ALT elevation and decreased HBeAg titer and/or reduced HBV DNA after delivery, may be good candidates for the CPIA therapy following delivery.</p>


Assuntos
Feminino , Humanos , Gravidez , Adenina , Usos Terapêuticos , Alanina Transaminase , Sangue , Antivirais , Usos Terapêuticos , Portador Sadio , Virologia , DNA Viral , Sangue , Quimioterapia Combinada , Antígenos de Superfície da Hepatite B , Sangue , Antígenos E da Hepatite B , Sangue , Hepatite B Crônica , Tratamento Farmacológico , Transmissão Vertical de Doenças Infecciosas , Interferon-alfa , Usos Terapêuticos , Organofosfonatos , Usos Terapêuticos , Polietilenoglicóis , Usos Terapêuticos , Complicações Infecciosas na Gravidez , Tratamento Farmacológico , Virologia , Terceiro Trimestre da Gravidez , Proteínas Recombinantes , Usos Terapêuticos , Timidina , Usos Terapêuticos
2.
Chinese Acupuncture & Moxibustion ; (12): 335-336, 2006.
Artigo em Chinês | WPRIM | ID: wpr-303075

RESUMO

<p><b>OBJECTIVE</b>To explore an effective method for increasing therapeutic effect on chronic prostatitis.</p><p><b>METHODS</b>Eighty-two cases of chronic prostatitis were randomly divided into two groups. The western medicine group of 42 cases were treated with routine western medicine combined with retention enteroclysis of 30 g Danshen (Red Sage Root) decoction; the warming needle moxibustion plus western medicine group of 40 cases were treated with the western medicine of the western medicine group plus warming needle moxibustion at Guanyuan (CV 4), Qihai (CV 6) and Zhongji (CV 3), etc.</p><p><b>RESULTS</b>In the warming needle moxibustion plus western medicine grbup, 20 cases were cured, 12 cases were markedly effective, 5 cases were effective and 3 cases were ineffective, the total effective rate being 92. 5%; and in the western medicine group, the corresponding figures were 13, 10, 7, 12 cases and 71.4%, with a significant difference between the two groups in the total effective rate (P < 0.05).</p><p><b>CONCLUSION</b>Warming needle moxibustion can increase the therapeutic effect on chronic prostatitis.</p>


Assuntos
Adulto , Humanos , Masculino , Pessoa de Meia-Idade , Doença Crônica , Moxibustão , Métodos , Prostatite , Terapêutica , Salvia miltiorrhiza
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA